Glucagon-Like Peptide-1 Decreases Intracerebral Glucose Content by Activating Hexokinase and Changing Glucose Clearance during Hyperglycemia

Brain Imaging in Alzheimer Disease

(2013) K. A. Johnson et al.   Cold Spring Harbor Perspectives in Medicine

Exenatide Alters Myocardial Glucose Transport and Uptake Depending on Insulin Resistance and Increases Myocardial Blood Flow in Patients with Type 2 Diabetes

(2012) M. Gejl et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in Type 2 diabetic rats

(2011) Vladimer Darsalia et al.   CLINICAL SCIENCE

Effects of Insulin on Brain Glucose Metabolism in Impaired Glucose Tolerance

(2011) J. Hirvonen et al.   DIABETES

Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes

(2011) Ann Mosegaard Bak et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Chronic mild cerebrovascular dysfunction as a cause for Alzheimer's disease?

(2010) Christian Humpel   EXPERIMENTAL GERONTOLOGY

Uncontrolled diabetes increases the risk of Alzheimer’s disease: a population-based cohort study

(2009) W. L. Xu et al.   DIABETOLOGIA

Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system

(2009) Alison Hamilton et al.   NEUROREPORT